IDH2 and astrocytoma (excluding glioblastoma): Amongst IDH-mutant gliomas, the homozygous deletion of CDKN2A/B has been shown to be an important marker for adverse clinical outcomes and this has been reflected in the updated grading scheme of the IDH-mutant astrocytoma [1].